Novartis's Phase III DM1 drug fails primary endpoint; maintains guidance despite setback
NVS sits 16% above its 52-week low of $121.57.
Summary
Novartis's Phase III trial for del-desiran in myotonic dystrophy type 1 (DM1) failed its primary endpoint, a setback for a drug targeting a disease with no approved treatments. Despite this, the company maintained its five-year sales growth guidance and provided updates on other pipeline drugs.
Key Events · Product Development and Regulatory · NVS
-
Phase III HARBOR Study Fails Primary Endpoint
The global Phase III HARBOR study evaluating delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1 (DM1) did not achieve statistical significance on its primary endpoint of video hand opening time (vHOT).
-
Future Development Path Under Review
Novartis will evaluate the full HARBOR dataset and engage with health authorities to determine the most appropriate development path for del-desiran, noting evidence of clinical activity in secondary endpoints and exploratory analyses.
-
Mixed Pipeline Updates
The company also announced FDA priority review for delpacibart zotadirsen in Duchenne muscular dystrophy (DMD44) and plans an FDA meeting for delpacibart braxlosiran in facioscapulohumeral muscular dystrophy (FSHD) based on previously reported positive Phase I/II biomarker data.
-
Sales Guidance Maintained
Novartis reiterated its 5-6% five-year sales CAGR guidance for 2025-2030, indicating confidence in its overall portfolio despite the trial setback.
Analysis · NVS · Life Sciences
Novartis announced that its Phase III HARBOR study for delpacibart etedesiran (del-desiran) in myotonic dystrophy type 1 (DM1) failed to meet its primary endpoint. This is a significant setback for a drug targeting a disease with high unmet need and no approved treatments, representing a loss of potential future revenue and R&D investment in this specific program. However, the company is maintaining its long-term sales growth guidance and highlighted positive progress for other pipeline assets, which helps to contain the overall negative impact on the diversified pharmaceutical giant.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NVS was trading at $140.55 on NYSE in the Life Sciences sector, with a market capitalization of approximately $283.6B. The 52-week trading range was $121.57 to $170.46. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.